SEC Filing | Braveheart Bio, Inc.

View:

SEC FORM 3SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chimovits Erez

(Last)

(First)

(Middle)

C/O BRAVEHEART BIO, INC.

ONE LETTERMAN DR., BLDG. A, SUITE A4-300

(Street)

SAN FRANCISCO

94129

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/05/2026

3. Issuer Name and Ticker or Trading Symbol
Braveheart Bio, Inc. [ BRVE ]
Foreign Trading Symbol

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,102,739	I	By OrbiMed Private Investments IX, LP⁽¹⁾⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Preferred Stock	⁽³⁾	⁽³⁾	Common Stock	9,132,420	⁽³⁾	I	By OrbiMed Private Investments IX, LP⁽¹⁾⁽²⁾

Explanation of Responses:

1. These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

2. Each of the Reporting Person, OrbiMed Advisors, and GP IX disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP IX is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

3. Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-4.38 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Paul Rickey, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Natalie Dement
and James Paul Rickey, signing singly, and with full power of
substitution, the undersigned's true and lawful attorney-in-fact to:

    (1) execute for and on behalf of the undersigned, in the undersigned's
    capacity as an officer, director, and/or securityholder of Braveheart
    Bio, Inc., a Delaware corporation (the "Company"), from time to time the
    following U.S. Securities and Exchange Commission ("SEC") forms: (i)
    Form 3, Initial Statement of Beneficial Ownership of Securities,
    including any attached documents; (ii) Form 4, Statement of Changes in
    Beneficial Ownership of Securities, including any attached documents;
    (iii) Form 5, Annual Statement of Beneficial Ownership of Securities in
    accordance with Section 16(a) of the Securities Exchange Act of 1934, as
    amended, and the rules thereunder, including any attached documents;
    and (iv) amendments of each thereof, in accordance with the
    Securities Exchange Act of 1934, as amended, and the rules thereunder,
    including any attached documents;

    (2) do and perform any and all acts for and on behalf of the undersigned
    which may be necessary or desirable to complete and execute any such
    Form 3, 4 or 5, or any amendment(s) thereto and timely file such form(s)
    with the SEC and any securities exchange, national association or
    similar authority; and

    (3) take any other action of any type whatsoever in connection with the
    foregoing which, in the opinion of such attorney-in-fact, may be
    legally required by, the undersigned, it being understood that the
    documents executed by such attorney-in-fact on behalf of the undersigned
    pursuant to this Power of Attorney shall be in such form and shall contain
    such terms and conditions as such attorney-in-fact may approve in
    furtherance of the foregoing.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full
power and authority to do and perform any and every act and thing whatsoever
requisite, necessary or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended.  The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee of
the Company. The undersigned may revoke this Power of Attorney at any time,
effective upon delivery of a signed written notice of revocation
to the Company, and this Power of Attorney shall automatically terminate
upon the undersigned ceasing to serve as a director of the Company, except
with respect to filings relating to transactions occurring prior to
such cessation.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of August 5, 2026.

/s/ Erez Chimovits
Signature


Erez Chimovits
Print Name